The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $402.49, representing a -1.13% change from its previous close.

TreeFrog Therapeutics is making Cambridgeport Labs the site of its U.S. headquarters, leasing just under 13,500 square feet at the campus. The cell therapy biotech is moving to its own dedicated lab ...

The stock's fall snapped a three-day winning streak.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

The startup is developing a kind of macrocyles, which share strengths of both small molecules and biologics, to make oral ...

Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today published a letter to shareholders highlighting the company ...

Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced that Chief Executive Officer, Madan Jagasia, M.D., will present at ...

By the end of March, the regulator could clear a highly anticipated pain drug from Vertex and a heart drug that’s critical to Alnylam’s future.

As the U.S. stock market begins to rebound from a sluggish start in 2025, with major indices like the S&P 500 and Nasdaq snapping multi-day losing streaks, investors are keenly observing opportunities ...